期刊文献+

利妥昔单抗注射液联合化疗治疗B细胞非霍奇金淋巴瘤疗效观察 被引量:11

Clinical Observation of B Cell Non-hodgkin's Lymphoma Treated with Rituxan Injection and Chemotherapy
下载PDF
导出
摘要 目的分析研究联合利妥昔单抗注射液以及化疗方法治疗B细胞非霍奇金淋巴瘤患者的临床疗效。方法参与本次研究的64例B细胞非霍奇金淋巴瘤患者均为我院2013年至2015年确诊收治的。按治疗方法的不同将患者随机分成2组,对照组(32例)采用的治疗方法为单纯的CHOP化疗治疗,试验组(32例)采用利妥昔单抗注射液以及化疗方法联合治疗。对所有患者进行连续4个周期的治疗后,对比分析两组患者的临床治疗效果,并比较两组患者不同治疗周期内的白细胞总数、淋巴细胞计数以及淋巴细胞比例。结果治疗后与治疗前相比,各组治疗方法均能起到一定的治疗效果,但试验组90.62%的总有效率要比对照组明显高(71.88%),差异有统计学意义(P<0.05)。两组患者的白细胞总数等各项指标均下降,但与对照组相比试验组患者的临床疗效更为显著。在不良反应的发生情况上,两组间差异无统计学意义(P>0.05)。结论在B细胞非霍奇金淋巴瘤患者的治疗过程中,联合利妥昔单抗注射液以及化疗方法的临床治疗效果要比单一的对患者进行化疗治疗疗效显著,可在临床广泛推广。 Objective Analysis and research of the clinical observation of patients with B cell non-hodgkin’s lymphoma treated with rituxan injection and chemotherapy. Methods 64 patients with B cell non-hodgkin’s lymphoma participated in this study were diagnosed from 2013 to 2015 in our hospital. According to the different treatments, patients were randomly divided into 2 groups. The control group (32 cases) :the therapy was simple CHOP chemotherapy;the experimental group (32 cases) :was given the rituxan injection and chemotherapy. All the patients were given 4 continuous cycles of treatment , then clinical therapeutic effects were compared between two groups and so did the different treatment cycle of the total white blood cells and lymphocyte count and lymphocyte proportion . Results After treatment, compared with before treatment, both therapies had certain therapeutic effect, but 90. 62% of the total effective rate of the experimental group is obviously higher than the control group(71. 88%), P〈0. 05, the difference was statistically significant. The indicators like total white blood cells of two groups were both decreased, but the clinical effect of the experimental group compared with control group was obvious. But on the occurrence of adverse reaction, there was no obvious difference between the two groups, that was no significant difference. Conclusion In the treatment of patients with B cell non-hodgkin’s lymphoma, the clinical curative effect of ituxan injection and chemotherapy was obvious than the chemotherapy only and that combining therapy can be widely applied in clinic.
作者 景莉
出处 《四川医学》 CAS 2016年第8期916-919,共4页 Sichuan Medical Journal
关键词 利妥昔单抗注射液 化疗 非霍奇金淋巴瘤 临床效果 rituxan injection chemotherapy non-hodgkin’s lymphoma clinical observation
  • 相关文献

参考文献10

二级参考文献69

  • 1吴宏菊,张清媛,陈德发,关小军,张伯龙,马军.美罗华联合CHOP方案与CHOP方案治疗初治弥漫性大B细胞淋巴瘤的临床对比研究[J].癌症,2005,24(12):1498-1502. 被引量:33
  • 2林明哲,李积德,吴密璐,李晓琴,李瑜英.利妥昔单抗联合化疗治疗侵袭性B细胞性非霍奇金淋巴瘤20例临床分析[J].青海医药杂志,2006,36(9):10-12. 被引量:7
  • 3凌云华,陆益,吴洪斌.利妥昔单抗及其联用CHOP方案的不良反应和处理[J].药物不良反应杂志,2006,8(5):355-358. 被引量:11
  • 4马军.利妥昔单抗在中国上市10年回顾.临床肿瘤学进展,2010,7(1):5-8.
  • 5Coiffier B,Thieblemont C, Van Den Neste E,et al. Long-term outcome of patients in the LNH-98.5 trial,the first randomized study comparing rit- uximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Grouped "Etudes des Lymphomesde 1 "Adulte [ J . Blood, 2010;116(12) :2040-5.
  • 6Grillo A J, Cheson BD, Homing S J, et al. Response criteria for NHL: im- portance of normal lymph node size and correlations with response rates [J. Ann Oneo,2000;11 (4):399-408.
  • 7Michallet AS, Coiffier B. Recent developments in the treatment of aggres- sive non-Hodgkin lymphoma[ J. Blood Rev ,2009 ;23 (1) :11-23.
  • 8Sonet A, Bosly A. Rituximab and chemotherapy in diffuse large B-cell lymphoma ( J 1. Expert Rev Anticancer Ther, 2009 ; 9 ( 6 ) : 719-26.
  • 9Rossi D, Rasi S, Franceschetti S, et al. Analysis of the host pharmaeogc- netic background for prediction of outcome an d toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 [ J 1 - Leukemia, 2009 ; 23 (6) :1118-26.
  • 10Swerdlow S, Campo E, Harris NL, et al. WHO Classifica- tion of Tumors of Haematopoietic and Lymphoid Tissue. IARC Lyon, 2008.

共引文献61

同被引文献79

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部